Bristol Myers Squibb Company $BMY Stock Holdings Lessened by JFS Wealth Advisors LLC

JFS Wealth Advisors LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 41.5% during the second quarter, HoldingsChannel reports. The institutional investor owned 2,121 shares of the biopharmaceutical company’s stock after selling 1,502 shares during the period. JFS Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $98,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. JB Capital LLC lifted its position in Bristol Myers Squibb by 7.6% in the 2nd quarter. JB Capital LLC now owns 5,579 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 393 shares during the last quarter. Robertson Stephens Wealth Management LLC lifted its position in Bristol Myers Squibb by 13.1% in the 2nd quarter. Robertson Stephens Wealth Management LLC now owns 10,396 shares of the biopharmaceutical company’s stock valued at $481,000 after purchasing an additional 1,205 shares during the last quarter. Cascade Investment Group Inc. lifted its position in Bristol Myers Squibb by 7.0% in the 2nd quarter. Cascade Investment Group Inc. now owns 6,114 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 400 shares during the last quarter. 3Chopt Investment Partners LLC lifted its position in Bristol Myers Squibb by 10.1% in the 2nd quarter. 3Chopt Investment Partners LLC now owns 62,786 shares of the biopharmaceutical company’s stock valued at $2,906,000 after purchasing an additional 5,760 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI lifted its position in Bristol Myers Squibb by 100.2% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 27,077 shares of the biopharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 13,551 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BMY. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Saturday, September 27th. Citigroup lowered their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, August 1st. Finally, Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $57.14.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $44.01 on Friday. The firm’s 50 day moving average is $46.26 and its 200-day moving average is $48.03. The stock has a market capitalization of $89.57 billion, a P/E ratio of 17.74, a P/E/G ratio of 2.25 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.6%. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.09% of the stock is owned by corporate insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.